ArticleTherapeutic advances in gastroenterology2020

Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland.

Pawel Petryszyn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.